304 related articles for article (PubMed ID: 10385787)
1. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
Dangas G; Colombo A
Am Heart J; 1999 Jul; 138(1 Pt 2):S16-23. PubMed ID: 10385787
[TBL] [Abstract][Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
3. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
Lincoff AM
Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
[TBL] [Abstract][Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Lincoff AM; Califf RM; Topol EJ
J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
[TBL] [Abstract][Full Text] [Related]
5. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
[TBL] [Abstract][Full Text] [Related]
6. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
8. Economic issues in glycoprotein IIb/IIIa receptor therapy.
Hillegass WB; Newman AR; Raco DL
Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
[TBL] [Abstract][Full Text] [Related]
9. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
10. Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Young JJ; Kereiakes DJ
J Interv Cardiol; 2002 Apr; 15(2):115-20. PubMed ID: 12063806
[No Abstract] [Full Text] [Related]
11. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
12. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
[TBL] [Abstract][Full Text] [Related]
13. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Araujo R; Agustà A
Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
[No Abstract] [Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
16. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Jennings LK
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
[TBL] [Abstract][Full Text] [Related]
17. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
18. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
19. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
Karvouni E; Katritsis DG; Ioannidis JP
J Am Coll Cardiol; 2003 Jan; 41(1):26-32. PubMed ID: 12570940
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
